Key Points {#d30e167}
==========

The Swedish indicators cover both drug- and diagnosis-specific aspects of quality of drug therapy in elderly persons.Since introduction in 2004, the Swedish indicators are widely implemented and have several applications in healthcare and research.Since 2005, there have been several signs of improvement of the quality of drug prescribing to the elderly population in Sweden.

Introduction {#Sec1}
============

Drug use is extensive in elderly persons \[[@CR1]--[@CR4]\]. Drug therapy in older people is also complicated by age-related pharmacokinetic and pharmacodynamic changes, which increase the sensitivity to many drugs. This, together with the extensive use of drugs and high prevalence of comorbidities, substantially increase the risk of untoward effects of drugs in old age \[[@CR5], [@CR6]\].

Inappropriate drug use (IDU) is an important health problem in elderly persons and is associated with adverse drug reactions, hospitalization, and mortality \[[@CR7]--[@CR11]\]. Previous studies have reported prevalences of IDU of 12--62 % in older people \[[@CR12]--[@CR16]\], varying greatly with regard to participants, setting and means of measuring IDU.

In Sweden, drug prescriptions to older people grew significantly from the late 1980s and onwards, particularly over the following decade when the mean number of drugs per person aged 80 years and older increased by over one-third \[[@CR17]\]. Furthermore, a study of a Swedish nationally representative survey reported a threefold increase in the prevalence of polypharmacy---as defined by the use of five or more drugs---from 18 % in 1992 to 42 % in 2002 \[[@CR18]\]. In two particularly vulnerable groups, nursing-home residents and elderly with multimorbidity, medication use was reported to amount to approximately ten drugs per person at the beginning of the 21st century \[[@CR19]--[@CR22]\].

Potentially, IDU was also abundant in Sweden at that time. In a study on drug use in nursing homes in 2002, the use of long-acting benzodiazepines and anticholinergic drugs---both with a high risk of side effects in older persons---was reported to be 15 and 20 %, respectively, and more than one in four residents were treated with three or more psychotropic drugs \[[@CR21]\]. Similar results were obtained from another study of 21 nursing homes in southern Sweden the same year \[[@CR20]\].

In the year 2000, the Swedish government commissioned the Swedish National Board of Health and Welfare to develop indicators for quality of drug therapy in the elderly. The first version of the indicators was released in 2004 \[[@CR23]\] and a revised version was issued in 2010 \[[@CR24]\]. In this review, we describe the Swedish indicators and compare them with other criteria/indicators for quality of medication treatment in elderly persons. We also describe how they have been employed over the years in healthcare and research, by authorities and by the elderly community in Sweden, and how the quality of drug use has changed over time.

Criteria for Quality of Drug Prescribing in Elderly Persons {#Sec2}
===========================================================

Inappropriate drug prescribing/use may be defined as the prescribing/use of drugs where the risk outweighs the benefit. Principally, this comprises the choice of drug, the dosage and length of therapy, the combination of drugs (drug duplication and drug--drug interactions \[DDIs\]), drug--disease interactions \[[@CR25]\] and, finally, underprescribing/use. The latter is also sometimes called therapy omission, i.e. the omission of drug treatment that is clinically indicated and likely to be beneficial for the patient.

Since the beginning of the 1990s, several sets of criteria have been developed to measure quality of drug use in older people and to guide healthcare professionals in ensuring the high quality and safety of drug therapy in this vulnerable patient group. The criteria can be divided into implicit and explicit \[[@CR26], [@CR27]\]. The implicit criteria are based on the clinical judgement of the drug therapy based on information about and from an individual patient. They rely largely on the expertise of the examiner and are generally time-consuming. In contrast, the explicit criteria consist of lists of criteria, mainly based on inappropriate drugs and drug treatment in certain medical conditions, that are to be generally applicable to patients in a target population, for example persons aged 65 years and older. They are intended to be easy to use and to enable a structured way of measuring/evaluating quality of drug use. The following sections briefly describe some of the most important explicit criteria. Their main features are also listed in Table [1](#Tab1){ref-type="table"}. All of the criteria listed below, other than the Australian Prescribing Indicators Tool (see Sect. [2.4](#Sec6){ref-type="sec"}), were derived from a consensus panel using a Delphi technique.Table 1Summary and comparison of the most common explicit criteria/indicators for quality of drug therapy in elderly peopleReferencesCriteria/indicatorsCountryTarget populationStructureAddressing prescribing omissionsOther featuresBeers et al. \[[@CR28]\]Beers' criteria, 1991USNursing home residents ≥65 years19 Criteria on drugs that should be avoided and 11 on doses, frequencies or durations not to be exceededNoBeers \[[@CR29]\]Beers' criteria, 1997USAll elderly ≥65 years28 Criteria on PIM use and 35 criteria on PIM in 15 diagnosesNoFick et al. \[[@CR30]\]Beers' criteria, 2003USAll elderly ≥65 years48 Drugs to be avoided. Drugs to be avoided in 20 diseases/conditionsNoAmerican Geriatrics Society \[[@CR31]\]Beers' criteria, 2012USAll elderly ≥65 years34 PIMs to avoid, PIMs to avoid in 14 diseases/syndromes, 13 drugs to be used with cautionNoMcLeod et al. \[[@CR33]\]McLeod's/Canadian criteriaCanadaAll elderly ≥65 years18 Contraindicated drugs, 16 drug--disease interactions, 4 DDINoInclude DDIsLaroche et al. \[[@CR34]\]French Consensus Panel ListFranceAll elderly ≥75 years29 Drugs to be avoided. Five criteria on drugs to be avoided in specific medical conditionsNoInclude drug duplication Suggest alternative therapiesGallagher et al. \[[@CR35]\]STOPP and STARTIreland/UKAll elderly ≥65 years65 Criteria on PIM (STOPP) 22 criteria on prescribing omissions (START)YesInclude drug duplication and DDIsBasger et al. \[[@CR36]\]Australian Prescribing Indicators ToolAustraliaAll elderly ≥65 years48 Prescribing indicators, including 18 regarding avoidance of medications in certain diseases/conditions and 19 therapy omissionsYesInclude DDIsRognstad et al. \[[@CR37]\]NORGEPNorwayAll elderly ≥70 years in general practice36 Criteria---21 on specific drugs and 15 on drug combinations, considered potentially inappropriateNoInclude DDIsHolt et al. \[[@CR38]\]PRISCUS ListGermanyAll elderly ≥65 years83 PIMsNoInclude information about therapeutic alternatives and precautionsSwedish National Board of Health and Welfare \[[@CR23], [@CR24]\]Swedish indicatorsSwedenAll elderly ≥75 years9 Drug-specific and 11 diagnosis-specific principal indicatorsYesInclude drug duplication and DDIs*STOPP* Screening Tool of Older People's Prescriptions, *START* Screening Tool to Alert to Right Treatment, *NORGEP* Norwegian General Practice, *PRISCUS* latin for 'time-honoured', *PIM* potentially inappropriate medication, *DDI* drug--drug interaction

Beers' Criteria {#Sec3}
---------------

Beers' criteria were the first explicit criteria for medication use in the elderly, first published in 1991, and have since then become the most cited and employed criteria in pharmacoepidemiological studies. While the first version \[[@CR28]\] only comprised drugs to be avoided and doses, frequencies or durations not to be exceeded, and was restricted to nursing-home residents, later updates \[[@CR29]--[@CR31]\] have included diagnosis/syndrome-specific criteria and target the elderly in general. Beers' criteria have been criticised \[[@CR26]\] mainly for being incomplete and poorly applicable outside the US. In fact, a large proportion of the included drugs have been reported not to be listed in European drug formularies \[[@CR32]\]. The most recent update \[[@CR31]\] shows improvements, but still lacks some aspects of quality of drug use, such as DDIs, drug duplications and underprescribing (therapy omissions).

McLeod's Criteria {#Sec4}
-----------------

In parallel with the second update of the Beers' criteria, McLeod and coworkers in Canada developed a list of 'inappropriate practices', with the aim of overcoming some of the limitations of the Beers' criteria. The practices were divided into three categories: drugs generally contraindicated for elderly people, drug--disease interactions and DDIs. For each practice, alternative therapies were recommended \[[@CR33]\].

French Consensus Panel List {#Sec5}
---------------------------

The French consensus panel list was the first European criteria to be acknowledged internationally \[[@CR34]\]. They were partly based on previous criteria, such as the Beers' and McLeod's criteria, but were much adapted to French drug formulary and guidelines. Apart from drugs to be avoided, they include aspects of drug duplications and drug--disease interactions. The list also suggests alternative drugs.

STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert to Right Treatment) {#Sec6}
-------------------------------------------------------------------------------------------------------------

The STOPP/START (Screening Tool of Older Person's Prescriptions/Screening Tool to Alert to Right Treatment) criteria \[[@CR35]\] were developed in Ireland, with the aim of creating a tool that is easy to use for the prescriber in everyday practice, yet also containing the common errors of drug treatment in elderly people, including potentially inappropriate medications (PIMs), drug duplications, DDIs and prescribing omissions. The criteria are divided into 65 criteria for potentially inappropriate prescriptions (STOPP) and 22 criteria for therapy omissions (START), each organised by physiological systems.

Australian Prescribing Indicators Tool {#Sec7}
--------------------------------------

These criteria are largely based on medical conditions, covering both drug--disease interactions and therapy omissions, and include aspects on drug dosing, renal function, DDIs and monitoring of drug effects \[[@CR36]\]. They also address some other relevant pieces of information; for example, 'blood pressure targets', 'risk factors for impaired renal function' and 'sources of calcium'. However, the criteria are mainly built on Australian information sources, such as data on common medical conditions and medications among older people, consensus documents and clinical guidelines, and may therefore not be fully applicable in other countries.

NORGEP (Norwegian General Practice) Criteria {#Sec8}
--------------------------------------------

The NORGEP (Norwegian General Practice) criteria published in 2009, were developed for patients in general practice and contain two lists, one about single drugs and drug dosages and one about drug combinations, considered potentially pharmacologically inappropriate for elderly patients \[[@CR37]\]. The NORGEP criteria have been criticised for containing several drugs that are rarely used in clinical practice \[[@CR26], [@CR27]\].

PRISCUS List {#Sec9}
------------

The PRISCUS list \[[@CR38]\] comprises 83 drugs among a total of 18 drug classes, rated as potentially inappropriate for elderly patients. They do not address other aspects of quality of drug use, but provide information regarding possible therapeutic alternatives, as well as precautions to be taken whenever the listed inappropriate medications are used.

The Swedish Indicators for Quality of Drug Therapy in the Elderly {#Sec10}
=================================================================

Development {#Sec11}
-----------

The starting point for the development of the Swedish indicators were the explicit criteria available at the time, i.e. the first version of the Beers criteria \[[@CR28]\] and the Canadian criteria \[[@CR33]\]. Other sources were recommendations and guidelines from Swedish authorities and organisations, including the Swedish Medical Products Agency, the Swedish National Board of Health and Welfare, the Swedish Council on Health Technology Assessment and the Swedish strategic programme against antibiotic resistance. DDIs were to be assessed according to the interaction database in Sweden at that time \[[@CR39]\].

The indicators were designed to be applicable to people aged 75 years and over, regardless of residence and other characteristics. It was decided to include both indicators about drug therapy regardless of diagnoses (drug-specific) and about drug therapy in some common conditions (diagnosis-specific). Novelties compared with previously published criteria at that time were the inclusion of indicators about drug duplications, drug use without proper indication and about dosage regimens. Moreover, the diagnosis-specific indicators were to include not only drug--disease interactions but also aspects of adherence to treatment recommendations. Thus, the indicators were supposed to be not only 'negative', reflecting IDU, but also 'positive', pointing at treatment that is potentially beneficial but sometimes omitted in eldercare.

The indicators were divided into (a) drug-specific, covering choice, indication and dosage of drugs, aspects of polypharmacy and DDIs; and (b) diagnosis-specific, covering rational, irrational and hazardous drug use in 11 common disorders in elderly people.

The indicators were validated through a consensus approach using a modified Delphi technique. The preliminary list was assessed by an expert panel consisting of a clinical pharmacologist, a pharmacist, two general practitioners, a geriatrician, a geropsychiatrist and a representative from the Swedish Medical Products Agency. After revision, a second proposal was published on the Web and the Swedish drug committees, heads of outpatient care and municipality chief nurses were asked to comment on the different indicators. Following a second revision, a final document was published in January 2004.

This first version comprised six principal drug-specific indicators, each containing 1--7 individual items, and 11 principal diagnosis specific indicators, each with 3--10 items on rational, irrational and hazardous drug treatment (Table [2](#Tab2){ref-type="table"}).Table 2Overview of the principal indicators in the first (2004) version of the Swedish indicators for quality of drug therapy in the elderlyIndicatorNo. of items*1. Drug-specific indicators* 1.1 Drugs that should be avoided unless specific reasons exist5 1.2 Drugs for which the use requires a correct and current indication7 1.3 Inappropriate dosage regimen3 1.4 Inappropriate daily dose7 1.5 Polypharmacy\
   Use of three or more psychotropic drugs\
   Drug duplication2 1.6 Drug combinations that may lead to clinically relevant drug--drug interactions1*2. Diagnosis-specific indicators* 2.1 Hypertension3 2.2 Ischemic heart disease--angina pectoris5 2.3 Heart failure7 2.4 Chronic obstructive pulmonary disease4 2.5 Diabetes, type 23 2.6 Gastroesophageal reflux disease and peptic ulcer disease5 2.7 Urinary tract infection10 2.8 Arthrosis4 2.9 Dementia3 2.10 Depression3 2.11 Sleep disturbance4

During 2008--2010 the indicators were revised and updated. This time, the procedure was somewhat different. The drug-specific indicators were reviewed in close collaboration with an expert group including one clinical pharmacologist, four pharmacists, one general practitioner, one geriatrician, one nurse, two municipality chief nurses, one pharmacoepidemiologist and one representative from the Swedish Medical Products Agency. The diagnosis-specific indicators were reviewed by representatives from the Swedish drug committees, each of the 11 principal indicators being independently revised by two different committees. The revision resulted in some major changes:one indicator was added regarding drug use in decreased renal function;one indicator was added regarding drug use and certain symptoms that may reflect adverse drug reactions;one indicator was added regarding the best choice of anxiolytic and hypnotic drugs;the indicator on arthrosis was replaced by an indicator on pain treatment.

In addition many indicators were updated to meet new recommendations, or to adapt to the current Swedish drug formulary, and in many cases were expanded.

The DDIs were now recommended to be assessed by using a new database, SFINX \[[@CR40]\], which since then has been implemented in most computerised patient records and other decision support systems in Sweden.

Structure {#Sec12}
---------

As in the first version from 2004 \[[@CR23]\], the updated (2010) version \[[@CR24]\] of the Swedish indicators are divided into drug-specific and diagnosis-specific indicators. All indicators have a common structure. They refer to the proportion of individuals using a certain inappropriate, rational, irrational or hazardous medication. Moreover, they do not specify levels of use but only state the preferred direction (standard): 'as low as possible' or 'as high as possible' (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}).Fig. 1The structure of a drug-specific indicator from the Swedish indicators for quality of drug therapy in the elderly, exemplified by indicator 1.1 'Drugs that should be avoided unless specific reasons exist', consisting of four items. ATC codes for the included drugs are presented within *brackets*. *ATC* Anatomical Therapeutic ChemicalFig. 2The structure of a diagnosis-specific indicator from the Swedish indicators for quality of drug therapy in the elderly, exemplified by indicator 2.2 'Ischemic heart disease--angina pectoris'. The indicator consists of six items, the first two about rational drug use and the remaining four about irrational or hazardous drug use. *ASA* acetylsalicylic acid

### Drug-Specific Indicators {#Sec13}

The updated version \[[@CR24]\] includes nine principal drug-specific indicators, each comprising 1--8 individual items (Table [3](#Tab3){ref-type="table"}; Fig. [1](#Tab1){ref-type="table"}). Anatomical Therapeutic Chemical (ATC) codes are included to define the drugs or drug groups. These indicators do not only define inappropriate drugs but also cover indication for drug use, dosage regimens, maximum daily doses of some important drugs, aspects of polypharmacy, DDIs, drugs that need dose adjustments in decreased renal function, drugs that are implicated in some important adverse drug reactions and some aspects on psychotropic drugs (Table [3](#Tab3){ref-type="table"}).Table 3Overview of the indicators in the second (2010) version of the Swedish indicators for quality of drug therapy in the elderlyIndicatorNo. of itemsExamples*1. Drug-specific indicators* 1.1 Drugs that should be avoided unless specific reasons exist4Long-acting benzodiazepines\
Drugs with significant anticholinergic properties\
Tramadol 1.2 Drugs for which the use requires a correct and current indication8NSAIDs\
Opioids\
SSRIs\
Antipsychotics\
Proton pump inhibitors 1.3 Inappropriate dosage regimen6Hypnotics, \>1 month of regular use\
Antiepileptics \>1 year without review\
Antipsychotics \>3 months without review 1.4 Inappropriate daily dose6Low-dose ASA, daily dose \>75 mg\
Risperidone, daily dose \>1.5 mg\
Oxazepam, daily dose \>30 mg 1.5 Polypharmacy3  Use of ten or more drugs  Use of three or more psychotropic drugs  Drug duplicationTwo or more opioids or hypnotics 1.6 Drug combinations that may lead to clinically relevant drug--drug interactions1Potassium + potassium-sparing agents\
Warfarin + NSAID 1.7 Drug use and renal function1Metformin, digoxin, potassium-sparing diuretics, atenolol 1.8 Drug use and certain symptoms3  Symptomatic orthostatic hypotensionCalcium channel blockers, antipsychotics  FallsDiuretics, hypnotics, antidepressants  Cognitive impairmentAnticholinergic drugs, opioids, antiepileptics 1.9 Psychotropic drugs2  Inappropriate anxiolytics and hypnoticsDiazepam, propiomazine  Best-choice anxiolytics and hypnoticsOxazepam, zopiclone*2. Diagnosis-specific indicators* 2.1 Hypertension4Hazardous: cardioselective calcium channel blocker in concurrent heart failure 2.2 Ischemic heart disease--angina pectoris6Rational: low-dose ASA, daily dose 75 mg 2.3 Heart failure9Rational: ACE inhibitor or angiotensin-II antagonist, β-receptor blocker\
Hazardous: NSAID, Cardioselective calcium channel blocker 2.4 Chronic obstructive pulmonary disease8Irrational: oral β-2-receptor agonist\
Hazardous: non-selective β-receptor blocker 2.5 Diabetes, type 24Hazardous: metformin with decreased renal function (estimated GFR \<60 ml/min), glibenclamide 2.6 GERD and peptic ulcer disease5Hazardous: NSAID with a history of GERD or peptic ulcer 2.7 UTI8Rational: pivmecillinam, nitrofurantoin or trimethoprim in UTI in women\
Hazardous: quinolone antibacterials 2.8 Pain6Hazardous: NSAIDs---continuous treatment, tramadol 2.9 Dementia5Rational: cholinesterase inhibitor or memantine, if effect is ascertained\
Hazardous: drugs with significant anticholinergic properties 2.10 Depression2Irrational: prescription of anxiolytics and hypnotics without antidepressant treatment 2.11 Sleep disturbance6Hazardous: triazolam, propiomazine, alimemazine, hydroxyzine and promethazine*NSAID* non-steroidal anti-inflammatory drug, *SSRI* selective serotonin reuptake inhibitor, *ASA* acetylsalicylic acid, *ACE* angiotensin-converting enzyme, *GERD* gastroesophageal reflux disease, *UTI* urinary tract infection, *GFR* glomerular filtration rate

### Diagnosis-Specific Indicators {#Sec14}

The 2010 update \[[@CR24]\] consists of 11 principal diagnosis-specific indicators, each covering 2--9 items on rational, irrational and hazardous drug treatment in common disorders in old age (Table [3](#Tab3){ref-type="table"}; Fig. [2](#Tab2){ref-type="table"}). The indicators on hazardous drug treatment represent drug--disease interactions, whereas those on rational drug treatment can be used to indicate therapy omissions. The indicators on irrational drug treatment include drugs that are neither hazardous nor beneficial with the specified diagnosis. They just represent an unnecessary addition to the drug list and, what is worse, may in some cases be a substitute for a better therapy. One example of this is oral β-2-receptor agonists in chronic obstructive pulmonary disease.

Comparison with Other Criteria/Indicators {#Sec15}
=========================================

The Swedish indicators were relatively comprehensive, particularly when it is considered that they were introduced as early as 2004. Indeed, at that time only the second update of the Beers' criteria \[[@CR30]\] and the McLeod criteria \[[@CR33]\] were available among the explicit criteria. The Swedish indicators not only comprised indicators on drug--disease interactions but also therapy omissions, both included among the diagnosis-specific indicators. In addition, both DDIs and drug duplications, as well as drug indications and dosages, were addressed. With the update 2010, more aspects on quality of medication were added; for example, on drug use in decreased renal function.

There are some clear differences between the Swedish indicators and other explicit criteria/indicators, in assigning medications as appropriate or inappropriate. Some of the drugs considered inappropriate in many other lists are even presented as rational therapy according to the Swedish indicators; for example, zopiclone, spironolactone and nitrofurantoin. Conversely, some drugs considered inappropriate by the Swedish indicators are not found in other lists; for example, tramadol and propiomazine.

Among the currently available criteria/indicators, the Swedish ones would be most comparable to the STOPP and START criteria \[[@CR35]\], which cover aspects on both IDU and therapy omissions, as well as DDIs and drug duplication.

Unlike the French consensus panel list \[[@CR34]\] and the PRISCUS list \[[@CR38]\], the Swedish indicator set does not include any information about therapeutic alternatives. However, this is intentional as one of the major aims of the indicators was that their use should not circumscribe the physician's opportunity to make a qualified decision.

Applications of the Swedish Indicators {#Sec16}
======================================

From the first version, the indicators were proposed to have the following fields of applications:as a support for prescribing drugs to elderly people;in different types of local follow-ups and interventions, for example drug utilisation reviews for elderly people in ordinary homes or nursing homes;for follow-up of prescription patterns;for national surveys and epidemiological studies.

The indicators can thus both provide support for improving the quality of older people's drug therapy and serve as tools for monitoring drug therapy.

Ten years after introduction, the indicators are well established in Swedish healthcare and have brought on several initiatives and applications along the way.

Actions from Drug and Therapeutic Committees {#Sec17}
--------------------------------------------

In 2006, the Swedish regional drug and therapeutic committees launched a national campaign for improving drug use in elderly people ('Nationella kraftsamlingen'), where one of the main objectives was to pave the way for the indicators to have an impact on Swedish healthcare. This resulted in not only several educational initiatives in geriatric pharmacology for healthcare personnel but also the creation of regional recommendations for drug therapy in older people, largely based on the indicators.

Prescribing Support {#Sec18}
-------------------

Within a year of publishing the first version of the indicators, quick reference guides were developed by some regional drug and therapeutic committees, summarising the most clinically relevant indicators, including inappropriate drugs---such as long-acting benzodiazepines and anticholinergic drugs---and drugs that should be prescribed with caution to elderly people; for example, non-steroidal anti-inflammatory drugs (NSAIDs), opioids and antipsychotics. Today, most Swedish counties have their own reference guide for drug prescribing to older persons.

Later, the indicators were also implemented in some computerised decision support systems for prescribing to elderly patients and drug utilisation reviews \[[@CR41]\].

Drug Utilisation Reviews {#Sec19}
------------------------

The Swedish indicators have been extensively used for many years in drug utilisation reviews for both nursing home and ambulatory older persons \[[@CR41], [@CR42]\]. Here, both the drug- and diagnosis-specific indicators can be used for identifying potential drug-related problems, such as the use of inappropriate drugs, duplicate use, DDIs and contraindicated drug use in some diseases. In a nursing-home study, where an extensive part of the Swedish indicators were used, these reviews led to marked improvements with respect to anticholinergic drugs (part of indicator 1.1; 40 % decrease), drug duplication (part of indicator 1.5; 30 % decrease), DDI (indicator 1.6; 41 % decrease) and hazardous drug use in some diagnoses (diagnosis-specific indicators; 48 % decrease) \[[@CR41]\].

National Benchmarking {#Sec20}
---------------------

Annually, since 2006 the Swedish National Board of Health and Welfare and the Swedish Association of Local Authorities and Regions (SALAR) have jointly published regional comparisons of quality and efficiency in Swedish healthcare, where the 21 counties are compared by using more than 100 indicators \[[@CR43]\]. Among these, five measure the quality of drug use in older people: drugs that should be avoided unless specific reasons exist (indicator 1.1), use of ten or more drugs and use of three or more psychotropic drugs (both from indicator 1.5), drug combinations that may lead to clinically relevant drug--drug interactions (indicator 1.6) and use of best-choice hypnotics (from indicator 1.9). These are applied to computerised analyses of the Swedish Prescribed Drug Register (SPDR), an individual-based register covering all dispensed prescriptions to the whole Swedish population, of which around 740,000 people are aged 75 years and older \[[@CR44]\].

Since 2008, a similar set of drug-specific indicators have been analysed at the municipality and urban district level and published annually on the Web in the so-called Äldreguiden ('Elderly guide'), providing elderly people and their relatives with the possibility of comparing the quality of eldercare, including levels of inappropriate medication, in different geographical areas of Sweden \[[@CR45]\].

Pay for Performance {#Sec21}
-------------------

In 2010, the Swedish government and SALAR made an agreement to support long-term improvement work with a focus on better quality and cohesiveness of the care of the most ill elderly persons. This included a pay for performance model, where the Swedish counties and municipalities were monitored with respect to different indicators of quality of care, and awarded when attaining the performance goals \[[@CR45]\]. Among the indicators is one set of three on the quality of drug use, including drugs that should be avoided unless specific reasons exist (indicator 1.1), NSAIDs and antipsychotics (both from indicator 1.2). During this initiative, in 2011--2014, drugs that should be avoided unless specific reasons exist (indicator 1.1) decreased by 27 %, NSAIDs by 28 % and antipsychotics by 12 % in persons 75 years and older.

Initiative from Pensioner Organisations {#Sec22}
---------------------------------------

'Koll på läkemedel' ('Keep track of your medications') is a collaboration between two of the largest Swedish pensioner organisations and one Swedish pharmacy company, working for better drug treatment in elderly people. Their purpose is to educate and support patients to improve their own treatment, and one of the more appreciated products is the 'Olämpliga listan' ('Inappropriate list'), derived from indicator 1.1.

Epidemiological Studies {#Sec23}
-----------------------

The Swedish indicators have been used in around 15 different epidemiological studies, describing quality of drug use in the elderly population in general \[[@CR44]\] and in nursing homes \[[@CR21], [@CR46], [@CR47]\], and investigating areas such as sex differences \[[@CR48]\], influence of education \[[@CR3], [@CR18]\], association with institutionalisation \[[@CR47]\], effect of multidose drug dispensing \[[@CR49], [@CR50]\] and the association with hospitalisation and mortality \[[@CR7]\]. Among others, these studies have demonstrated significant associations between IDU and female sex \[[@CR48]\], institutional living \[[@CR47]\], low educational attainment \[[@CR3]\] and multidose dispensing \[[@CR49]\].

Regulations {#Sec24}
-----------

In 2012, the Swedish National Board of Health and Welfare \[[@CR51]\] launched regulations imposing healthcare providers to offer medication reviews to all patients aged 75 years or older, using ≥5 drugs. In the associated guidance \[[@CR52]\], they recommend the use of the indicators in these reviews.

Improvements in Quality of Drug Use {#Sec25}
===================================

Since 2005, we have observed signs of improvement in the quality of drug prescribing in the elderly population in Sweden. In a report from the National Board of Health and Welfare \[[@CR53]\], analyses of the SPDR showed that the prescribing of drugs that should be avoided unless specific reasons exist (indicator 1.1) had decreased by 36 % between 2006 and 2012 in persons aged 80 years and older. Similarly, drug combinations that may lead to clinically relevant drug--drug interactions (1.6) decreased by 26 %. Among psychotropic drugs, antipsychotics reduced by 41 %, anxiolytics by 12 % and hypnotics by 10 %. In contrast, the polypharmacy indicator use of 10 or more drugs (1.5) did not change (11 % in both 2006 and 2012) in this age group.

A more recent study \[[@CR54]\] largely confirms these results. Measurements from the SPDR between 2006 and 2013 show improvements in people aged 75 years and older, according to all but one drug-specific indicator, covering drugs that should be avoided unless specific reasons exist (1.1), use of three or more psychotropic drugs (1.5) and best-choice anxiolytics and hypnotics (1.9). However, the indicator use of 10 or more drugs (1.5) was virtually unchanged. The authors conclude that "prescribers appear to be more likely to change their prescribing patterns for the elderly than previously assumed" \[[@CR54]\].

A few studies from other countries have also examined the trend in inappropriate medication over time. In an American study of community-dwelling elderly people ≥65 years of age, IDU, as evaluated by using the Beers' 1997 criteria \[[@CR29]\], declined from 24.8 % in 1995 to 21.3 % in 1999, i.e. a 14 % reduction \[[@CR55]\]. An Italian study of a similar age group of community dwellers, over the same time period, evaluated with Beers' 1991 criteria \[[@CR28]\], reported a greater decrease, by 44 % (from 9.1 to 5.1 %); however, at the same time, potentially major DDIs increased by 19 % \[[@CR56]\].

A study using a French update of the Beers 1997 \[[@CR29]\] criteria showed a mean annual decrease in PIM rate of 3.6 % between 1995 and 2004 \[[@CR57]\]. However, the decrease was only seen for two drug groups (cerebral vasodilators and long-acting benzodiazepines).

In a more recent study from Germany, comparing 2003 and 2009, PIM prevalence evaluated by using the German PRISCUS list, in ambulatory people aged 75 years or more, was reduced from 29 to 25 %, corresponding to a 14 % decrease \[[@CR58]\].

Thus, the decrease in IDU observed in the Swedish elderly population since 2006 is largely beyond what has been observed in other studies of long-term trends in medication use. Although we cannot establish a causal relationship between this positive development and the advent of the Swedish indicators, it is reasonable to assume that they have contributed to this positive trend.

Many types of interventions can lead to a reduction in IDU in elderly people, ranging from educational interventions, computerised support systems, pharmacist interventions, geriatric medicine services, multidisciplinary team reviews and regulatory policies \[[@CR59]\]. As described above, the Swedish indicators have, to some extent, had an impact on all these types of interventions. Thus, the Swedish indicators may have promoted the 'combined efforts' \[[@CR59]\] that are probably necessary to make a sustainable improvement of the quality of drug treatment in elderly patients.

Limitations {#Sec26}
===========

A general weakness of consensus-based criteria/indicators is that they can never be fully applicable to the heterogeneous population of drug responders that aged people represent. They are a crude tool and their use needs to be adjusted to the clinical situation. Drug use deemed inappropriate may sometimes be indicated for the individual patient or in a particular clinical situation, when the benefit is estimated to outweigh the risk. This means, for example, that this type of criteria/indicators may overestimate the prevalence of inappropriate drug prescribing in epidemiological studies.

Another limitation is the general lack of information regarding adherence to the drug therapy. This is common to all measures of drug use, but non-adherence is more frequent in the elderly population with polypharmacy \[[@CR60]\], and most likely also with IDU.

Finally, we do not know to what extent the improved quality of drug therapy in older people in Sweden has translated into improved health of the elderly. This needs to be further investigated in terms of public health outcomes in the Swedish elderly population.

Conclusions {#Sec27}
===========

The indicators on the quality of drug therapy in the elderly, developed by the Swedish National Board of Health and Welfare, were first published in 2004 and updated in 2010. They comprise several aspects of quality of drug prescribing, including inappropriate drugs, indication of drug use, drug dosage, polypharmacy, drug duplications, DDIs, drug use in decreased renal function, drug symptom/disease interactions and therapy omissions.

The indicators have been well received by Swedish healthcare, authorities, politicians, researchers and pensioner organisations. During the 10 years since their release, they have been employed in many different activities to improve the quality of drug use in elderly persons, including prescribing support, drug utilisation reviews and national benchmarking. They also form the basis for recommendations on drug treatment in old age, several scientific publications, and have promoted many educational initiatives in this area, both for healthcare personnel and for older persons and their relatives.

During this time, several measures of the quality of drug use in the Swedish elderly population have shown significant improvements; for example, a decreased prevalence of drugs that should be avoided, drug combinations that may lead to DDIs and several types of psychotropic drugs.

Therefore, the Swedish indicators may be seen as a successful national initiative that has translated into local initiatives, research in geriatric pharmacoepidemiology, and contributed to better drug treatment in old age.
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